The New Jersey attorney general has asked Amgen to submit documentation on the marketing push and prescription activity for its best-selling psoriasis treatment, Enbrel, following claims of unethical marketing by two former sales representatives. Amgen said it would cooperate with the investigation and said the accusations have no merit.

Related Summaries